Homestead Advisers’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.4M | Buy |
370,921
+900
| +0.2% | +$51.7K | 0.53% | 53 |
|
|
2026
Q1 | $22.4M | Sell |
370,021
-4,200
| -1% | -$245K | 0.6% | 50 |
|
|
2025
Q4 | $20.2M | Sell |
374,221
-50,168
| -12% | -$2.41M | 0.53% | 49 |
|
|
2025
Q3 | $19.1M | Sell |
424,389
-539,800
| -56% | -$25.2M | 0.46% | 51 |
|
|
2025
Q2 | $44.6M | Buy |
964,189
+3,700
| +0.4% | +$182K | 1.06% | 45 |
|
|
2025
Q1 | $58.6M | Hold |
960,489
| – | – | 1.43% | 37 |
|
|
2024
Q4 | $54.3M | Buy |
960,489
+35,800
| +4% | +$2M | 1.31% | 38 |
|
|
2024
Q3 | $47.8M | Sell |
924,689
-700
| -0.1% | -$32.8K | 1.14% | 44 |
|
|
2024
Q2 | $38.4M | Sell |
925,389
-15,900
| -2% | -$711K | 0.95% | 45 |
|
|
2024
Q1 | $50.9M | Sell |
941,289
-1,300
| -0.1% | -$66.2K | 1.19% | 39 |
|
|
2023
Q4 | $48.4M | Buy |
942,589
+1,600
| +0.2% | +$84K | 1.24% | 38 |
|
|
2023
Q3 | $54.6M | Buy |
940,989
+14,500
| +2% | +$888K | 1.52% | 32 |
|
|
2023
Q2 | $59.2M | Buy |
926,489
+4,500
| +0.5% | +$302K | 1.57% | 32 |
|
|
2023
Q1 | $63.9M | Buy |
921,989
+101,000
| +12% | +$7.12M | 1.78% | 28 |
|
|
2022
Q4 | $59.1M | Buy |
820,989
+200
| +0% | +$15.1K | 1.58% | 31 |
|
|
2022
Q3 | $58.4M | Sell |
820,789
-26,400
| -3% | -$1.92M | 1.77% | 26 |
|
|
2022
Q2 | $65.2M | Hold |
847,189
| – | – | 1.85% | 23 |
|
|
2022
Q1 | $61.9M | Sell |
847,189
-126,900
| -13% | -$8.52M | 1.51% | 31 |
|
|
2021
Q4 | $60.7M | Sell |
974,089
-7,200
| -0.7% | -$422K | 1.4% | 29 |
|
|
2021
Q3 | $58.1M | Buy |
981,289
+3,900
| +0.4% | +$257K | 1.41% | 29 |
|
|
2021
Q2 | $65.3M | Sell |
977,389
-13,600
| -1% | -$887K | 1.51% | 25 |
|
|
2021
Q1 | $62.6M | Sell |
990,989
-50,500
| -5% | -$3.14M | 1.5% | 27 |
|
|
2020
Q4 | $64.6M | Sell |
1,041,489
-25,300
| -2% | -$1.56M | 1.6% | 27 |
|
|
2020
Q3 | $64.3M | Sell |
1,066,789
-118,200
| -10% | -$7.11M | 1.76% | 23 |
|
|
2020
Q2 | $69.7M | Buy |
1,184,989
+1,600
| +0.1% | +$95.7K | 1.79% | 24 |
|
|
2020
Q1 | $66M | Sell |
1,183,389
-34,288
| -3% | -$2.1M | 1.94% | 19 |
|
|
2019
Q4 | $78.2M | Sell |
1,217,677
-11,630
| -0.9% | -$666K | 1.63% | 26 |
|
|
2019
Q3 | $62.3M | Sell |
1,229,307
-120,023
| -9% | -$5.64M | 1.26% | 32 |
|
|
2019
Q2 | $61.2M | Sell |
1,349,330
-1,025,670
| -43% | -$47.8M | 1.16% | 33 |
|
|
2019
Q1 | $113M | Sell |
2,375,000
-325,000
| -12% | -$16.2M | 2.12% | 20 |
|
|
2018
Q4 | $140M | Hold |
2,700,000
| – | – | 2.72% | 13 |
|
|
2018
Q3 | $168M | Hold |
2,700,000
| – | – | 2.57% | 13 |
|
|
2018
Q2 | $149M | Hold |
2,700,000
| – | – | 2.35% | 13 |
|
|
2018
Q1 | $171M | Hold |
2,700,000
| – | – | 2.56% | 9 |
|
|
2017
Q4 | $165M | Hold |
2,700,000
| – | – | 2.37% | 11 |
|
|
2017
Q3 | $172M | Hold |
2,700,000
| – | – | 2.62% | 7 |
|
|
2017
Q2 | $150M | Hold |
2,700,000
| – | – | 2.35% | 10 |
|
|
2017
Q1 | $147M | Hold |
2,700,000
| – | – | 2.34% | 9 |
|
|
2016
Q4 | $158M | Hold |
2,700,000
| – | – | 2.48% | 6 |
|
|
2016
Q3 | $146M | Sell |
2,700,000
-1,300
| -0% | -$83.5K | 2.41% | 7 |
|
|
2016
Q2 | $199M | Hold |
2,701,300
| – | – | 3.41% | 1 |
|
|
2016
Q1 | $173M | Buy |
+2,701,300
| New | +$170M | 3.09% | 2 |
|
Other funds holding BMY
Homestead Advisers's BMY Position: Q2 2026 in Review
Homestead Advisers increased its Bristol-Myers Squibb (BMY) stake by 0.24% in Q2 2026, buying an estimated $51.7K and bringing the position to 370,921 shares worth $21.4M. The position accounts for 0.53% of the portfolio, ranked #53.
Homestead Advisers first reported a position in BMY in Q1 2016 and has held it in 42 quarters since. The position peaked at $199M in Q2 2016. 2,514 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Homestead Advisers held 370,921 shares of Bristol-Myers Squibb worth $21.4M as of Q2 2026.
- Homestead Advisers bought 900 Bristol-Myers Squibb shares in Q2 2026, an estimated $51.7K.
- Bristol-Myers Squibb made up 0.53% of Homestead Advisers's portfolio in Q2 2026, its #53 holding.
- Homestead Advisers first reported a position in Bristol-Myers Squibb in Q1 2016 and has held it in 42 quarters since.
- Homestead Advisers's Bristol-Myers Squibb position peaked at $199M in Q2 2016.
- 2,514 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Homestead Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.